about
Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cellsHIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast.Pleiotropic effects of cardioactive glycosides.Overcoming multidrug resistance by targeting mitochondria with NO-donating doxorubicins.The association of statins plus LDL receptor-targeted liposome-encapsulated doxorubicin increases in vitro drug delivery across blood-brain barrier cells.Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1alpha and P-glycoprotein overexpression.Classical inhibitors of NOX NAD(P)H oxidases are not specific.Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway.iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells.Fluoride effects: the two faces of janus.Human γδ T-cell responses in infection and immunotherapy: common mechanisms, common mediators?Nanoparticle- and liposome-carried drugs: new strategies for active targeting and drug delivery across blood-brain barrier.Omega 3 fatty acids chemosensitize multidrug resistant colon cancer cells by down-regulating cholesterol synthesis and altering detergent resistant membranes composition.Doxorubicin-antioxidant co-drugs.Temozolomide down-regulates P-glycoprotein in human blood-brain barrier cells by disrupting Wnt3 signaling.Digoxin and ouabain induce the efflux of cholesterol via liver X receptor signalling and the synthesis of ATP in cardiomyocytes.Atorvastatin modulates anti-proliferative and pro-proliferative signals in Her2/neu-positive mammary cancer.Nitric oxide donor doxorubicins accumulate into Doxorubicin-resistant human colon cancer cells inducing cytotoxicity.Modulation of doxorubicin resistance by the glucose-6-phosphate dehydrogenase activity.Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells.Antioxidants prevent the RhoA inhibition evoked by crocidolite asbestos in human mesothelial and mesothelioma cells.Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process.High aspect ratio materials: role of surface chemistry vs. length in the historical "long and short amosite asbestos fibers".Geranylgeraniol prevents the cytotoxic effects of mevastatin in THP-1 cells, without decreasing the beneficial effects on cholesterol synthesis.A LDL-masked liposomal-doxorubicin reverses drug resistance in human cancer cells.Asbestos induces doxorubicin resistance in MM98 mesothelioma cells via HIF-1alpha.The NADPH oxidase inhibitor apocynin induces nitric oxide synthesis via oxidative stress.Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells.Asbestos induces nitric oxide synthesis in mesothelioma cells via Rho signaling inhibition.Iron-loaded synthetic chrysotile: a new model solid for studying the role of iron in asbestos toxicity.Statins revert doxorubicin resistance via nitric oxide in malignant mesothelioma.The NADPH oxidase inhibitor apocynin (acetovanillone) induces oxidative stress.Different cellular responses evoked by natural and stoichiometric synthetic chrysotile asbestos.Potential toxicity of nonregulated asbestiform minerals: balangeroite from the western Alps. Part 3: Depletion of antioxidant defenses.Potential toxicity of nonregulated asbestiform minerals: balangeroite from the western Alps. Part 2: Oxidant activity of the fibers.Diphenyleneiodonium inhibits the cell redox metabolism and induces oxidative stress.Artemisinin inhibits inducible nitric oxide synthase and nuclear factor NF-kB activation.Doxorubicin induces an increase of nitric oxide synthesis in rat cardiac cells that is inhibited by iron supplementation.Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/glycogen synthase-3 kinase/β-catenin pathway.The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vγ9Vδ2 T cell activation by dendritic cells.
P50
Q28486174-4EEFF486-93E2-43AC-90A1-5C22E8DB60F3Q34118293-957AB55D-F354-4B9A-9182-408D8BDF91BFQ34156408-BFEED07A-E780-4042-842A-0AAD8B3C9F33Q35907770-498BFB84-E331-43DB-ADDC-F14F11352D7FQ36446501-194842B7-8E1A-4588-BAF4-06678776F68BQ37230670-F6736C2A-1B8B-4082-AB40-1CCED1A62DC2Q37294085-ECA552E6-3096-402A-9AA0-D009F9AC9B89Q37294327-A9B3F765-6B85-45EA-90A4-C8E2553AE520Q37448441-5EB28444-16DC-48C1-9AC6-8681ADB6BE3AQ37758880-09DD9037-2C8F-49E9-909A-6B6C6B6F7935Q38027044-1D6F8582-8D8C-4D67-9E1B-4995D5B52486Q38122736-0EEE20CA-9A84-4DBD-B1DB-C4E85E1A3BF5Q39063524-52B3368F-50BB-4C98-A1F3-D856F35DB0F3Q39105965-50699C31-C29F-47B8-B6B5-027C948ECBA4Q39138906-E9BFF279-00CE-47D3-92DA-50B6C977C345Q39305936-AF8C1313-98F3-48E7-A1E0-AE118DAAB003Q39498061-44F941B2-40A3-40E4-B3B9-3466BD2A5E0BQ39514398-4461635E-CC90-469F-B53E-6DB1647ED2FDQ39523446-1E91A931-72D1-4F6F-AAB3-1F934BCDAB7CQ39558821-9765B896-83EC-4AD3-B8EE-D1E00383DB48Q39604188-7A65C180-7A00-4F40-8DF3-FFA08C926CA8Q39640530-8E757DD2-A2C2-4B29-8407-2BB236D126A2Q39666241-4C52DF6E-27A3-4B9B-8F87-3277111469F1Q39779125-190E089A-A1AE-45DC-A473-578B465D2FC9Q39827717-DEC93110-2C57-495A-A4DF-54F286F17E06Q39995585-800211FC-E639-47F2-80C6-1F2D94CF4E10Q40018868-ACF60356-B4E9-44D6-A88E-4FF77377B0D9Q40094556-C43D910E-3D72-4151-A663-134DC04CFB72Q40166725-8F79EF71-00B2-4114-BDD2-81185DA3E468Q40168225-43128442-82D4-4B83-8431-A0681D11BD66Q40322360-5C51FF9C-8DC4-401A-AE49-FB714F5DB9F2Q40381744-68E2D445-6C0E-4A81-B31E-150AC4A4B96AQ40394078-239AC4D6-7688-4633-8903-D968C07DE2DEQ40452430-40F0B2DF-6B60-498A-A4AC-3B60A9288C27Q40452438-E3A47F54-326C-4C63-BA67-B6DBD2CACA18Q40516925-0D9DB6D7-4765-4446-A22A-261051576975Q40629009-0B26D008-0BC1-4B81-86C6-9B62492B1213Q40682543-BBB9C1E2-1E5C-495A-92F2-B25700EB20C2Q41833207-1D3A59F7-C65D-4D46-88A9-28107036936CQ42211743-9B7774A8-93E6-47C7-960E-88725C1DD607
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Chiara Riganti
@ast
Chiara Riganti
@en
Chiara Riganti
@es
Chiara Riganti
@nl
Chiara Riganti
@sl
type
label
Chiara Riganti
@ast
Chiara Riganti
@en
Chiara Riganti
@es
Chiara Riganti
@nl
Chiara Riganti
@sl
prefLabel
Chiara Riganti
@ast
Chiara Riganti
@en
Chiara Riganti
@es
Chiara Riganti
@nl
Chiara Riganti
@sl
P108
P106
P108
P1153
6602480015
P21
P31
P496
0000-0001-9787-4836